Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
Treament | Trials | |||||
---|---|---|---|---|---|---|
Demonstrated or suggested benefit | Inconclusive results | Uncertain results | Safety results | |||
Immunostimulants drugs | demonstrated 12 % decrease in death D28 demonstrated 11 % decrease in deaths demonstrated 14 % decrease in clinical deterioration demonstrated 11 % increase in clinical improvement suggested 78 % increase in clinical improvement (28-day) demonstrated 15 % increase in clinical improvement (time to event analysis only) suggested 3.0-fold increase in viral clearance | inconclusive results for: 14-days deaths; death or transfer to ICU; deaths (time to event analysis only); clinical improvement (14-day); clinical improvement (7-day); death or ventilation; hospital discharge; hospitalization; mechanical ventilation; mechanical ventilation (time to event analysis only); radiologic improvement (14-day); Recovery (time to event analysis only); viral clearance (time to event analysis only); viral clearance by day 14; off oxygenation; recovery; composite safety outcome ; related SAE (TRSAE); serious adverse events; superinfection; adverse events | - | - | ||
Immunosuppressants drugs | demonstrated 30 % decrease in clinical deterioration demonstrated 25 % increase in clinical improvement suggested 37 % increase in clinical improvement (14-day) demonstrated 15 % increase in clinical improvement (time to event analysis only) | inconclusive results for: death or transfer to ICU; deaths (time to event analysis only); clinical improvement (21-day); clinical improvement (28-day); clinical improvement (7-day); hospital discharge; radiologic improvement (14-day); viral clearance (time to event analysis only); ICU admission; recovery; related AE (TRAE); serious adverse events; acute kidney injury ; adverse events; elevated liver enzymes; Myocardial infarction ; venous thromboembolism | suggested 50 % decrease in superinfection but the degree if certainty is unassessable suggested 84 % decrease in arrhythmia but the degree if certainty is unassessable | |||
anti-inflammatory therapies | inconclusive results for: death D28; death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement (28-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; mechanical ventilation; viral clearance ; viral clearance by day 7; ICU admission; adverse events; cardiovascular or renal events | suggested 10.3-fold increase in clinical improvement but the degree if certainty is unassessable suggested 3.5-fold increase in recovery but the degree if certainty is unassessable | - | |||
corticosteroids | inconclusive results for: death D28; death or transfer to ICU; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; mechanical ventilation; ICU admission; serious adverse events; superinfection | suggested 78 % increase in viral clearance but the degree if certainty is unassessable | - | |||
Kinase inhibitors | none | - | - | - | ||
leflunomide | none | inconclusive results for: deaths; clinical deterioration; viral clearance ; related SAE (TRSAE); adverse events | - | - | ||
Apilimod | 0 | - | - | - | - | |
inhaled corticosteroids | 0 | - | - | - | - | |
meplazumab | 0 | - | - | - | - | |
pirfenidone | 0 | - | - | - | - | |
Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
sargramostim | 0 | - | - | - | - | |
statins | 0 | - | - | - | - | |
thymosin | 0 | - | - | - | - |